Navigation Links
Elcelyx Therapeutics' NewMet for Type 2 Diabetes Meets Primary Endpoint in Phase 2b Study
Date:9/4/2013

SAN DIEGO, Sept. 4, 2013 /PRNewswire/ -- Elcelyx Therapeutics announced today that NewMet™, the delayed-release formulation of generic metformin for the treatment of patients with Type 2 diabetes, met its primary study endpoint with statistically significant reductions in fasting plasma glucose at four weeks of treatment compared to placebo. 

The results from the randomized, 240-patient, multicenter U.S. Phase 2b trial confirm previous studies that showed NewMet reduced fasting plasma glucose to a similar extent as generic metformin but at plasma exposure levels previously shown to be as much as 65% lower than comparable doses of generic metformin.

The double-blind, dose-finding trial evaluated NewMet once-daily doses of 1,000, 800 and 600 milligrams compared to placebo. There were also two comparator arms with Glucophage XR dosed once-daily at 1,000 and 2,000 milligrams. Secondary endpoints through 12 weeks include changes in fasting plasma glucose, hemoglobin A1c, body weight and measures of safety and tolerability. Twelve-week results are expected in late October.

The results at four weeks provide confirmation that the primary site of metformin activity is the lower bowel and not the circulation.  The reduced systemic absorption of NewMet indicates that it may be an appropriate treatment for Type 2 diabetes patients who have renal impairment and are contraindicated for metformin use due to the risk of lactic acidosis, a life-threatening condition that can result from metformin build-up in the blood.

About Elcelyx Therapeutics, Inc.

Elcelyx Therapeutics is developing pharmaceutical product candidate NewMet™ for use by Type 2 diabetes patients who have difficulty tolerating generic metformin or are contraindicated for its use. NewMet presents a near-term, blockbuster commercial opportunity. Elcelyx is based in San Diego, CA. For more information, vi
'/>"/>

SOURCE Elcelyx Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Elcelyx Therapeutics Reports Positive Data for NewMet in Type 2 Diabetes at 2013 American Diabetes Association Scientific Sessions
2. Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
3. Elcelyx Therapeutics Completes $20 Million Series C Financing to Advance NewMet and Lovidia
4. Elcelyx Therapeutics Names Mark Wiggins Senior Vice President of Business Development, Ginger Graham to Board of Directors
5. Aratana Therapeutics Drives Awareness of Pet Therapeutic Opportunity During "CVC Week" in Kansas City
6. Mast Therapeutics To Present At The Rodman & Renshaw 15th Annual Healthcare Conference On September 10
7. PTC Therapeutics to Present at Upcoming Investor Conferences
8. Aratana Therapeutics to Host Pet Therapeutics Primer and Product Update Event
9. Carolus Therapeutics and The Alpha-1 Project Collaborate to Validate CT-2009 Target as Important in Human Disease
10. Echo Therapeutics Announces Management Changes
11. aTyr Pharma Awarded Two Patents from USPTO to Support Development of New Therapeutics Based on Physiocrine Biology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)...  Decision Resources Group finds that the Asia Pacific ... China , India , ... through 2023. Dental implant procedure volumes will grow as physicians are ... Other key findings from Decision Resources Group,s coverage of the ... , Dental implant penetration: Penetration of dental implants among the ...
(Date:9/30/2014)... , Sept. 30, 2014   Easy Breathe ... destination , today announced that it now offers the ... AirSense CPAPs are the first sleep apnea therapy devices ... simple and easy to track and share real-time data ... effectiveness of their CPAP therapy.  In addition, the internal ...
(Date:9/30/2014)... , N.J. and NEW BRUNSWICK, N.J., Sept. 30, 2014 ... agreement that allows Kessler Foundation and New Jersey ... biomedical research, education and patient care programs has ... and chief executive officer of Kessler Foundation and ... Jersey Health Foundation. "The experience of ...
Breaking Medicine Technology:Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2
... Leading academic and industry specialists ... discuss the challenges that could see R&D grind to a ... Selecting and screening the correct polymorphs and ensuring ... effective way has never been more vital. According to George ...
... Ontario, Canada, Oct. 27, 2011 Valeant Pharmaceuticals International, Inc. ... of 8,523,517 additional common shares of Afexa Life Sciences Inc. ... of the offer by its wholly-owned subsidiary 1625907 Alberta Ltd. ... of Afexa. As all of the conditions to the offer ...
Cached Medicine Technology:Pharma Industry Unites With Academia to Tackle Ongoing Problem 2Valeant Announces Take-Up of Additional Afexa Shares and Special Meeting of Shareholders of Afexa to Approve Its Privatization 2Valeant Announces Take-Up of Additional Afexa Shares and Special Meeting of Shareholders of Afexa to Approve Its Privatization 3
(Date:9/30/2014)... of allergy-related sudden deaths in the U.S., according to ... conducted by researchers at Montefiore Medical Center ... Yeshiva University . The study, published online today in ... also found that the risk of fatal drug-induced allergic ... and that such deaths increased significantly in the U.S. ...
(Date:9/30/2014)... NV (PRWEB) September 30, 2014 Elevate ... helping people perform better in and out of the gym ... memory has caught the attention of Shane Michaels, prompting an ... grind, fatigue is the reason most people simply just don’t ... that means staying focused at work, getting the motivation to ...
(Date:9/30/2014)... 2014 With the flu season ... every day, it’s a perfect time to announce ... system is an electro-static disinfectant delivery system that ... normally missed with spray-on disinfectant applicators. , The ... an electrostatic negative charge to the disinfecting solution. ...
(Date:9/30/2014)... Bifidobacteria, the primary bacteria found in the large ... so a high Bifido probiotic can help replenish this ... Men’s Complete contains 90 Billion live probiotic cultures, ... support a healthy large intestine (colon) where elimination occurs ... cultures from 7 Lactobacillus strains to help maintain a ...
(Date:9/30/2014)... gene mutation that causes a rare premature aging disease ... the rapid, unstoppable cell division that makes cancer so ... and the U-M Health System recently discovered a protein ... which precious hematopoietic stem cells can,t regenerate and make ... prone to cancer and bone marrow failure. , ...
Breaking Medicine News(10 mins):Health News:Comprehensive Study of allergic deaths in US finds medications are main culprit 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:Columbus Janitorial Company Announces New Disinfecting System for your workplace 2Health News:ReNew Life Introduces Ultimate Flora™ Men’s Complete Probiotic 90 Billion—Comprehensive Probiotic Support Just for Men 2Health News:Disease decoded: Gene mutation may lead to development of new cancer drugs 2
... , FRIDAY, Dec. 17 (HealthDay News) Christmas and ... of year, which makes it all the more stressful when ... of the year when people are especially vulnerable to depression, ... System, said in a university news release. Shopping and entertaining ...
... hot new Social Graph app, researchers in the ADVANCE ... network mapping to help women scientists and engineers supercharge ... buildings and balance sheets. They,re webs of human interaction," ... Women in Technology and the ADVANCE project leader. "The ...
... Dec. 16 (HealthDay News) -- Naturally occurring high hemoglobin levels ... on dialysis, and there is no need to lower these ... in red blood cells that carries oxygen. Progressive anemia ... advanced chronic kidney disease. The anemia must be treated with ...
... HealthDay Reporter , THURSDAY, Dec. 16 (HealthDay News) ... of the drug Avastin to fight breast cancer, citing ... potential for serious side effects. But the recommendation, ... at a news conference, will not immediately affect breast ...
... , , , , , ... , , AUDIO: ... from Washington University... , Click here for more information. ... , , , , , ...
... Dec. 16 (HealthDay News) -- A new study suggests that ... can bring to their companies. "If anything, our research ... longer and perform better than an applicant whose scores make ... of management at the University of South Carolina, said in ...
Cached Medicine News:Health News:Surviving the Holiday Blues 2Health News:Mapping faculty social networks helps female faculty move ahead at NJIT 2Health News:Mapping faculty social networks helps female faculty move ahead at NJIT 3Health News:Naturally High Hemoglobin Levels May Not Threaten Kidney Patients 2Health News:FDA Advises Against Avastin as Treatment for Breast Cancer 2Health News:FDA Advises Against Avastin as Treatment for Breast Cancer 3Health News:MRI scans reveal brain changes in people at genetic risk for Alzheimer's 2Health News:MRI scans reveal brain changes in people at genetic risk for Alzheimer's 3Health News:MRI scans reveal brain changes in people at genetic risk for Alzheimer's 4Health News:MRI scans reveal brain changes in people at genetic risk for Alzheimer's 5Health News:Overqualified Workers May Be Less Likely to Quit Jobs 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: